A Small Molecule Activator of P300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2016 Jun 4

PMID 27256286

Citations 21

Authors

Shane V Hegarty

Eimear Oleary

Franziska Solger

Joanna Stanicka

Aideen M Sullivan

Gerard W OKeeffe

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease characterised by motor and non-motor symptoms, resulting from the degeneration of nigrostriatal dopaminergic neurons and peripheral autonomic neurons. Given the limited success of neurotrophic factors in clinical trials, there is a need to identify new small molecule drugs and drug targets to develop novel therapeutic strategies to protect all neurons that degenerate in PD. Epigenetic dysregulation has been implicated in neurodegenerative disorders, while targeting histone acetylation is a promising therapeutic avenue for PD. We and others have demonstrated that histone deacetylase inhibitors have neurotrophic effects in experimental models of PD. Activators of histone acetyltransferases (HAT) provide an alternative approach for the selective activation of gene expression, however little is known about the potential of HAT activators as drug therapies for PD. To explore this potential, the present study investigated the neurotrophic effects of CTPB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide), which is a potent small molecule activator of the histone acetyltransferase p300/CBP, in the SH-SY5Y neuronal cell line. We report that CTPB promoted the survival and neurite growth of the SH-SY5Y cells, and also protected these cells from cell death induced by the neurotoxin 6-hydroxydopamine. This study is the first to investigate the phenotypic effects of the HAT activator CTPB, and to demonstrate that p300/CBP HAT activation has neurotrophic effects in a cellular model of PD.

Citing Articles

Targeting neuronal epigenomes for brain rejuvenation.

Zocher S EMBO J. 2024; 43(16):3312-3326.

PMID: 39009672 PMC: 11329789. DOI: 10.1038/s44318-024-00148-8.

Capsid-mediated control of adeno-associated viral transcription determines host range.

Loeb E, Havlik P, Elmore Z, Rosales A, Fergione S, Gonzalez T Cell Rep. 2024; 43(3):113902.

PMID: 38431840 PMC: 11150003. DOI: 10.1016/j.celrep.2024.113902.

Unlocking the epigenetic symphony: histone acetylation's impact on neurobehavioral change in neurodegenerative disorders.

Basavarajappa B, Subbanna S Epigenomics. 2024; 16(5):331-358.

PMID: 38321930 PMC: 10910622. DOI: 10.2217/epi-2023-0428.

The evolution of small molecule enzyme activators.

Dow L, Case A, Paustian M, Pinkerton B, Simeon P, Trippier P RSC Med Chem. 2023; 14(11):2206-2230.

PMID: 37974956 PMC: 10650962. DOI: 10.1039/d3md00399j.

Cigarette smoke extract induces the senescence of endothelial progenitor cells by upregulating p300.

Liang G, He Z, Peng H, Zeng M, Zhang X Tob Induc Dis. 2023; 21:122.

PMID: 37794858 PMC: 10546488. DOI: 10.18332/tid/170581.

References

Selvi B, Jagadeesan D, Suma B, Nagashankar G, Arif M, Balasubramanyam K . Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. Nano Lett. 2008; 8(10):3182-8. DOI: 10.1021/nl801503m. View

Gomez-Santos C, Ambrosio S, Ventura F, Ferrer I, Reiriz J . TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells. Brain Res. 2002; 958(1):152-60. DOI: 10.1016/s0006-8993(02)03680-6. View

Chen Y, Monteith N, Law P, Loh H . Dynamic association of p300 with the promoter of the G protein-coupled rat delta opioid receptor gene during NGF-induced neuronal differentiation. Biochem Biophys Res Commun. 2010; 396(2):294-8. DOI: 10.1016/j.bbrc.2010.04.083. View

Jin H, Kanthasamy A, Ghosh A, Yang Y, Anantharam V, Kanthasamy A . α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci. 2011; 31(6):2035-51. PMC: 3041642. DOI: 10.1523/JNEUROSCI.5634-10.2011. View

Hegarty S, Collins L, Gavin A, Roche S, Wyatt S, Sullivan A . Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons. Neuromolecular Med. 2014; 16(2):473-89. DOI: 10.1007/s12017-014-8299-5. View

Zhu M, Li W, Lu C . Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci Ther. 2013; 20(4):308-16. PMC: 6493005. DOI: 10.1111/cns.12217. View

Hegarty S, Sullivan A, OKeeffe G . BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons. Mol Cell Neurosci. 2013; 56:263-71. DOI: 10.1016/j.mcn.2013.06.006. View

Steketee M, Moysidis S, Weinstein J, Kreymerman A, Silva J, Iqbal S . Mitochondrial dynamics regulate growth cone motility, guidance, and neurite growth rate in perinatal retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci. 2012; 53(11):7402-11. PMC: 3484733. DOI: 10.1167/iovs.12-10298. View

Devipriya B, Kumaradhas P . Charge density distribution and the electrostatic moments of CTPB in the active site of p300 enzyme: a DFT and charge density study. J Theor Biol. 2013; 335:119-29. DOI: 10.1016/j.jtbi.2013.06.001. View

10.

McMillan C, Sharma R, Ottenhof T, Niles L . Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci Lett. 2007; 419(3):202-6. DOI: 10.1016/j.neulet.2007.04.029. View

11.

Tao K, Matsuki N, Koyama R . AMP-activated protein kinase mediates activity-dependent axon branching by recruiting mitochondria to axon. Dev Neurobiol. 2013; 74(6):557-73. DOI: 10.1002/dneu.22149. View

12.

Yang X, Seto E . HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007; 26(37):5310-8. DOI: 10.1038/sj.onc.1210599. View

13.

Gutierrez H, OKeeffe G, Gavalda N, Gallagher D, Davies A . Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the phosphorylation status of p65/RelA. J Neurosci. 2008; 28(33):8246-56. PMC: 3512167. DOI: 10.1523/JNEUROSCI.1941-08.2008. View

14.

Wong K, Sharma A, Awasthi S, Matlock E, Rogers L, Van Lint C . HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB. J Biol Chem. 2004; 280(10):9390-9. DOI: 10.1074/jbc.M408643200. View

15.

Goldstein D, Holmes C, Li S, Bruce S, Metman L, Cannon 3rd R . Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000; 133(5):338-47. DOI: 10.7326/0003-4819-133-5-200009050-00009. View

16.

Kazantsev A, Thompson L . Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008; 7(10):854-68. DOI: 10.1038/nrd2681. View

17.

Abel T, Zukin R . Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008; 8(1):57-64. PMC: 2405764. DOI: 10.1016/j.coph.2007.12.002. View

18.

Kontopoulos E, Parvin J, Feany M . Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006; 15(20):3012-23. DOI: 10.1093/hmg/ddl243. View

19.

Bedard C, Wallman M, Pourcher E, Gould P, Parent A, Parent M . Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism Relat Disord. 2011; 17(8):593-8. DOI: 10.1016/j.parkreldis.2011.05.012. View

20.

Valor L, Viosca J, Lopez-Atalaya J, Barco A . Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des. 2013; 19(28):5051-64. PMC: 3722569. DOI: 10.2174/13816128113199990382. View